A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

Recruiting

mNEXSPIKE®A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

Sponsor:

Moderna

Code:

NCT07089706

Conditions

COVID-19

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Accepted

Interventions

mRNA-1283.251 Variant-containing Formulation

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-21. This information was provided to ClinicalTrials.gov by ModernaTX, Inc. on 2025-10-14.